Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07423611CT.gov ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07102940CT.gov Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07410559CT.gov Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07527806CT.gov Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging | — | Not Yet Recruiting | — | — | — |
NCT07570368CT.gov Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07217990CT.gov Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07432178CT.gov CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） | — | Not Yet Recruiting | — | — | — |
NCT07317778CT.gov Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07358806CT.gov Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07246317CT.gov Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | — | Not Yet Recruiting | — | — | — |
Show 284 more trialsShow fewer
NCT07102381CT.gov A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT07136974CT.gov Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. | — | Not Yet Recruiting | — | — | — |
NCT07083505CT.gov A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07003074CT.gov A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06914440CT.gov Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06996093CT.gov Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor | — | Not Yet Recruiting | — | — | — |
NCT07137793CT.gov Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients | — | Recruiting | — | — | — |
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06927180CT.gov SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | — | Recruiting | — | — | — |
NCT06348134CT.gov Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | — | Recruiting | — | — | — |
NCT07615751CT.gov Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT06038539CT.gov Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | — | Terminated | — | — | — |
NCT06409390CT.gov Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | — | Recruiting | — | — | — |
NCT07386938CT.gov A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06439693CT.gov The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06470633CT.gov To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07335081CT.gov ctDNA in HER2+ EBC Neoadjuvant Treatment | — | Recruiting | — | — | — |
NCT06375707CT.gov Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06254690CT.gov The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | — | Recruiting | — | — | — |
NCT06186700CT.gov Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer | — | Completed | — | — | — |
NCT06079983CT.gov JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | — | Recruiting | — | — | — |
NCT05900206CT.gov Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT06107673CT.gov Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | — | Recruiting | — | — | — |
NCT05929768CT.gov Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05914753CT.gov Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT05256745CT.gov RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05673629CT.gov Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT05918328CT.gov Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | — | Recruiting | — | — | — |
NCT05430347CT.gov Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT06009627CT.gov Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | — | Completed | — | — | — |
NCT05074290CT.gov Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | — | Recruiting | — | — | — |
NCT05381038CT.gov Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | — | Recruiting | — | — | — |
NCT05953909CT.gov A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). | — | Unknown | — | — | — |
NCT05475678CT.gov Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05638594CT.gov Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | — | Recruiting | — | — | — |
NCT05645380CT.gov Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | — | Active Not Recruiting | — | — | — |
NCT05296798CT.gov A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05430399CT.gov Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT04329065CT.gov Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | — | Recruiting | — | — | — |
NCT05319873CT.gov Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05207514CT.gov Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | — | Terminated | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05287308CT.gov Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | — | Not Yet Recruiting | — | — | — |
NCT06618014CT.gov Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) | — | Active Not Recruiting | — | — | — |
NCT05159193CT.gov Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | — | Recruiting | — | — | — |
NCT05114720CT.gov Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | — | Completed | — | — | — |
NCT04136782CT.gov Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT04137640CT.gov Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | — | Unknown | — | — | — |
NCT05165225CT.gov Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | — | Active Not Recruiting | — | — | — |
NCT05656079CT.gov To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | — | Unknown | — | — | — |
NCT04717531CT.gov Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | — | Unknown | — | — | — |
NCT04872985CT.gov Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04665986CT.gov Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT04629846CT.gov Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. | — | Completed | — | — | — |
NCT04400695CT.gov A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | — | Unknown | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04367090CT.gov Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | — | Completed | — | — | — |
NCT05629949CT.gov A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
NCT04266249CT.gov CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | — | Active Not Recruiting | — | — | — |
NCT04187898CT.gov Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | — | Completed | — | — | — |
NCT03611985CT.gov Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | — | Withdrawn | — | — | — |
NCT04165993CT.gov Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04182568CT.gov Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer | — | Unknown | — | — | — |
NCT03756064CT.gov Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT01907529CT.gov A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer | — | Unknown | — | — | — |
NCT03609047CT.gov Adjuvant Palbociclib in Elderly Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05301530CT.gov Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | — | Completed | — | — | — |
NCT03894007CT.gov Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | — | Terminated | — | — | — |
NCT04264468CT.gov Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test | — | Unknown | — | — | — |
NCT03742986CT.gov Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | — | Completed | — | — | — |
NCT03863223CT.gov A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03199885CT.gov Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03876587CT.gov Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC | — | Unknown | — | — | — |
NCT03839823CT.gov Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03493854CT.gov A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT03387553CT.gov HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | — | Completed | — | — | — |
NCT05301010CT.gov Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT03373708CT.gov Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | — | Unknown | — | — | — |
NCT03507465CT.gov Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT03949634CT.gov Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | — | Unknown | — | — | — |
NCT03264547CT.gov A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | — | Completed | — | — | — |
NCT03161353CT.gov Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | — | Active Not Recruiting | — | — | — |
NCT02953340CT.gov SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | — | Completed | — | — | — |
NCT03497702CT.gov Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | — | Unknown | — | — | — |
NCT07407244CT.gov Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03123770CT.gov Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | — | Unknown | — | — | — |
NCT03144947CT.gov Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients | — | Unknown | — | — | — |
NCT02915744CT.gov A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | — | Completed | — | — | — |
NCT03084237CT.gov Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02532400CT.gov Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients | — | Terminated | — | — | — |
NCT02643420CT.gov SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) | — | Completed | — | — | — |
NCT02605915CT.gov Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT02627248CT.gov Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02402712CT.gov Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT03017404CT.gov A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer | — | Completed | — | — | — |
NCT02947061CT.gov S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02229084CT.gov Vaccination of High Risk Breast Cancer Patients | — | Completed | — | — | — |
NCT02339532CT.gov Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | — | Completed | — | — | — |
NCT03221881CT.gov Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer | — | Completed | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02934828CT.gov Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer | — | Unknown | — | — | — |
NCT02187744CT.gov A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | — | Completed | — | — | — |
NCT01646034CT.gov High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02144012CT.gov A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT02027376CT.gov Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients | — | Completed | — | — | — |
NCT02365805CT.gov Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer | — | Completed | — | — | — |
NCT01964391CT.gov A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT02003209CT.gov Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01966471CT.gov A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01876251CT.gov A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01939054CT.gov Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients | — | Unknown | — | — | — |
NCT02980965CT.gov Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer | — | Completed | — | — | — |
NCT01792050CT.gov Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02472964CT.gov Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. | — | Completed | — | — | — |
NCT01622361CT.gov Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | — | Unknown | — | — | — |
NCT01564056CT.gov Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment | — | Active Not Recruiting | — | — | — |
NCT01611051CT.gov A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01492101CT.gov The BEACON Study (Breast Cancer Outcomes With NKTR-102) | — | Completed | — | — | — |
NCT01503905CT.gov Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | — | Unknown | — | — | — |
NCT01526499CT.gov Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01137994CT.gov A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01479036CT.gov Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer | — | Unknown | — | — | — |
NCT01501487CT.gov MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | — | Completed | — | — | — |
NCT01985841CT.gov Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer | — | Terminated | — | — | — |
NCT01446016CT.gov Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) | — | Completed | — | — | — |
NCT01367028CT.gov A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer | — | Completed | — | — | — |
NCT01220128CT.gov Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | — | Terminated | — | — | — |
NCT01660542CT.gov An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01351597CT.gov A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00964704CT.gov A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT02119715CT.gov A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy | — | Completed | — | — | — |
NCT01256567CT.gov A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer | — | Completed | — | — | — |
NCT01229605CT.gov Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT01485926CT.gov A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | — | Completed | — | — | — |
NCT01208480CT.gov Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer | — | Completed | — | — | — |
NCT01540110CT.gov Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses | — | Completed | — | — | — |
NCT01270373CT.gov NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? | — | Unknown | — | — | — |
NCT01120184CT.gov A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | — | Completed | — | — | — |
NCT01156753CT.gov A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | — | Completed | — | — | — |
NCT01314833CT.gov Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy | — | Completed | — | — | — |
NCT00774241CT.gov PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01041235CT.gov Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | — | Completed | — | — | — |
NCT01038804CT.gov A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00852332CT.gov Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer | — | Terminated | — | — | — |
NCT01069081CT.gov Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00934856CT.gov A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00944424CT.gov Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca | — | Unknown | — | — | — |
NCT00917748CT.gov Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF) | — | Completed | — | — | — |
NCT00845910CT.gov A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00832338CT.gov Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores | — | Terminated | — | — | — |
NCT00769470CT.gov Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT00678626CT.gov Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT00820872CT.gov Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00847444CT.gov Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention | — | Unknown | — | — | — |
NCT00841828CT.gov Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | — | Completed | — | — | — |
NCT01180335CT.gov Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer | — | Completed | — | — | — |
NCT01044485CT.gov Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00712881CT.gov Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00667251CT.gov Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00679341CT.gov A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | — | Completed | — | — | — |
NCT00937417CT.gov S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT00703326CT.gov Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | — | Completed | — | — | — |
NCT00830544CT.gov Study of Neoadjuvant Chemotherapy of Breast Cancer | — | Unknown | — | — | — |
NCT00776724CT.gov Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm | — | Completed | — | — | — |
NCT00717951CT.gov A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT00645333CT.gov Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00637897CT.gov Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00604435CT.gov Neoadjuvant Endostatin and Chemotherapy for Breast Cancer | — | Completed | — | — | — |
NCT00490646CT.gov A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00721747CT.gov Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer | — | Unknown | — | — | — |
NCT00600249CT.gov Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer. | — | Completed | — | — | — |
NCT00600496CT.gov A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | — | Completed | — | — | — |
NCT00559754CT.gov A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer. | — | Completed | — | — | — |
NCT00479856CT.gov Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | — | Terminated | — | — | — |
NCT00576901CT.gov A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer. | — | Terminated | — | — | — |
NCT00567554CT.gov Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | — | Completed | — | — | — |
NCT00630032CT.gov Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer | — | Completed | — | — | — |
NCT00538525CT.gov Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00434031CT.gov CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT00607438CT.gov A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00864175CT.gov Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00525759CT.gov Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer | — | Completed | — | — | — |
NCT00499122CT.gov NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | — | Completed | — | — | — |
NCT00493649CT.gov Adj TC + Herceptin Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00539968CT.gov A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | — | Terminated | — | — | — |
NCT00535509CT.gov Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00524459CT.gov Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Terminated | — | — | — |
NCT00432172CT.gov Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00433589CT.gov Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | — | Completed | — | — | — |
NCT00450892CT.gov Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | — | Completed | — | — | — |
NCT01622478CT.gov Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes | — | Completed | — | — | — |
NCT00356681CT.gov A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | — | Terminated | — | — | — |
NCT00372424CT.gov Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | — | Completed | — | — | — |
NCT00404066CT.gov Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | — | Completed | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00391092CT.gov A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT00377780CT.gov Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00365365CT.gov Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | — | Completed | — | — | — |
NCT00527449CT.gov Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel | — | Completed | — | — | — |
NCT00377559CT.gov Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00322400CT.gov Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | — | Completed | — | — | — |
NCT00462696CT.gov MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer | — | Completed | — | — | — |
NCT02005549CT.gov A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer | — | Completed | — | — | — |
NCT00288444CT.gov Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT00494481CT.gov E3 Breast Cancer Taxotere Combination | — | Completed | — | — | — |
NCT00310089CT.gov AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00274456CT.gov Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00253318CT.gov RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00258375CT.gov OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00327288CT.gov Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | — | Completed | — | — | — |
NCT00251433CT.gov GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00268918CT.gov Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | — | Completed | — | — | — |
NCT00179309CT.gov Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer | — | Completed | — | — | — |
NCT01172028CT.gov Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00217815CT.gov Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer | — | Completed | — | — | — |
NCT00232479CT.gov Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer | — | Completed | — | — | — |
NCT00127933CT.gov XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00212095CT.gov Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer | — | Completed | — | — | — |
NCT02392845CT.gov A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study | — | Completed | — | — | — |
NCT00193180CT.gov Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00203372CT.gov Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | — | Completed | — | — | — |
NCT01025349CT.gov Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00155259CT.gov Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00091442CT.gov A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00206518CT.gov Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | — | Completed | — | — | — |
NCT00665457CT.gov Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | — | Terminated | — | — | — |
NCT00584012CT.gov A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer | — | Terminated | — | — | — |
NCT00524810CT.gov Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00309920CT.gov Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | — | Unknown | — | — | — |
NCT00086957CT.gov Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00129896CT.gov Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | — | Completed | — | — | — |
NCT00148668CT.gov Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00250874CT.gov Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00080665CT.gov Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00225056CT.gov Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma | — | Terminated | — | — | — |
NCT00070252CT.gov Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00311636CT.gov Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00319618CT.gov Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00251329CT.gov Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery | — | Unknown | — | — | — |
NCT00063934CT.gov Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00148902CT.gov Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | — | Completed | — | — | — |
NCT00471432CT.gov OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00198237CT.gov Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | — | Completed | — | — | — |
NCT00214864CT.gov A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00053911CT.gov Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | — | Terminated | — | — | — |
NCT00247481CT.gov ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00544765CT.gov Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer | — | Completed | — | — | — |
NCT00089479CT.gov A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00352378CT.gov Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer | — | Completed | — | — | — |
NCT00206466CT.gov Biologic Correlative Taxotere/AC | — | Completed | — | — | — |
NCT02748213CT.gov A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00044993CT.gov Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00039520CT.gov Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT01222052CT.gov 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT00206453CT.gov Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT00312208CT.gov Docetaxel in Breast Cancer | — | Completed | — | — | — |
NCT00028873CT.gov R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | — | Completed | — | — | — |
NCT00047099CT.gov Combination Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00193037CT.gov Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00004888CT.gov Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00028483CT.gov Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer | — | Terminated | — | — | — |
NCT00020332CT.gov Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
NCT00006261CT.gov Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer | — | Withdrawn | — | — | — |
NCT00006682CT.gov Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00012311CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer | — | Unknown | — | — | — |
NCT00004906CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00206505CT.gov Neoadjuvant Taxotere | — | Completed | — | — | — |
NCT00190489CT.gov A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00003352CT.gov Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003103CT.gov Chemotherapy in Treating Patients With Solid Tumors | — | Completed | — | — | — |
NCT00003066CT.gov Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00002544CT.gov Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00041171CT.gov Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | — | Withdrawn | — | — | — |
NCT00793377CT.gov Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Fudan University | Approved | BB · 69 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Breast Neoplasm | — | P4 | BB · 71 |
| Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/docetaxel-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →